Rocket Pharmaceuticals Inc

Latest Results (11.10.2025):

Rocket Pharmaceuticals Inc reported its financial results for the fourth quarter and full year of 2024, highlighting significant progress in its gene therapy pipeline and maintaining a strong cash position to support ongoing and future operations.

Strong Cash Position

As of December 31, 2024, Rocket Pharmaceuticals Inc held $372.3 million in cash, cash equivalents, and investments. This financial strength is expected to fund operations into the third quarter of 2026, supporting the production of AAV cGMP batches and the continued development of six clinical and preclinical programs.

Research and Development Expenses

Research and development expenses for the twelve months ended December 31, 2024, were $171.2 million, a decrease of $15.1 million compared to $186.3 million for the same period in 2023. The reduction was primarily due to lower manufacturing and development costs, partially offset by increased professional fees and stock compensation expenses.

General and Administrative Expenses

General and administrative expenses rose to $102.0 million for the twelve months ended December 31, 2024, from $73.3 million in 2023. This increase was driven by higher commercial preparation costs, legal expenses, and compensation and benefit expenses.

Net Loss

Rocket Pharmaceuticals Inc reported a net loss of $258.7 million, or $2.73 per share, for the twelve months ended December 31, 2024, compared to a net loss of $245.6 million, or $2.92 per share, for the same period in 2023.

Successful Public Offering

In December 2024, Rocket Pharmaceuticals Inc completed a public offering, raising net proceeds of $182.5 million. The offering included approximately 15.2 million shares of common stock and pre-funded warrants, reinforcing the company's financial stability.